In situ radiotherapy with 111In-pentetreotide: State of the art and perspectives

K. E. McCarthy, E. A. Woltering, L. B. Anthony

Research output: Contribution to journalReview articlepeer-review

85 Scopus citations


111In-pentetreotide (Octreoscan®) and other radiolabeled somatostatin analogs are useful in the management of well differentiated neuroendocrine malignancies such as carcinoid or islet cell neoplasms. These radiopeptides bind to membrane bound somatostatin receptors (sst 1-5) which are over-expressed in a wide variety of neoplasms, especially those arising from the neuroectoderm. Imaging advances allow for the noninvasive determination of the presence of sst receptors by combining radioactivity [111Indium with a somatostatin analog, DTPA-D-phe1-octreotide (pentetreotide)]. Radiolabeled somatostatin analogs bind to membrane receptors and internalization of the complex occurs. Auger emitting somatostatin analogs offer a novel and significantly less toxic approach to controlling neoplastic diseases by delivering targeted radiation specifically to receptor bearing cells while sparing receptor negative cells. Responses of 62-69% in 85 patients with metastatic neuroendocrine tumors treated with high dose (6-19.6 GBq) 111In-pentetreotide, specifically targeting tumor somatostatin receptors, have been reported. Objective responses observed included biochemical and radiographic responses with prolonged survival. This article will discuss and review the multi-center data available to date, the mechanisms of action of radiolabeled somatostatin analogs, dosimetry, clinical response parameters, and toxicity.

Original languageEnglish
Pages (from-to)88-95
Number of pages8
JournalQuarterly Journal of Nuclear Medicine
Issue number1
StatePublished - 2000


  • Auger
  • Cytotoxicity
  • Electron
  • Indium radioisotopes
  • Neuroendocrine tumors radiotherapy
  • Radiotherapy
  • Receptors, somatostatin
  • Somatostatin
  • Targeted therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'In situ radiotherapy with 111In-pentetreotide: State of the art and perspectives'. Together they form a unique fingerprint.

Cite this